43 Stock Overview
electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
electroCore, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.67 |
52 Week High | US$9.96 |
52 Week Low | US$2.50 |
Beta | 1.21 |
1 Month Change | 0% |
3 Month Change | -13.44% |
1 Year Change | -15.30% |
3 Year Change | -70.37% |
5 Year Change | n/a |
Change since IPO | -97.98% |
Recent News & Updates
Recent updates
Shareholder Returns
43 | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 0% | 2.4% | 2.5% |
1Y | -15.3% | 7.2% | 7.0% |
Return vs Industry: 43E0 underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: 43E0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
43 volatility | |
---|---|
43 Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 43E0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 43E0's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 62 | Dan Goldberger | https://www.electrocore.com |
electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults; Truvaga for the support of general health and wellbeing; and TAC-STIM, a form of nVNS for human performance. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years.
electroCore, Inc. Fundamentals Summary
43 fundamental statistics | |
---|---|
Market cap | €29.25m |
Earnings (TTM) | -€20.66m |
Revenue (TTM) | €8.72m |
3.4x
P/S Ratio-1.4x
P/E RatioIs 43 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
43 income statement (TTM) | |
---|---|
Revenue | US$9.47m |
Cost of Revenue | US$1.48m |
Gross Profit | US$8.00m |
Other Expenses | US$30.45m |
Earnings | -US$22.45m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -4.73 |
Gross Margin | 84.43% |
Net Profit Margin | -236.96% |
Debt/Equity Ratio | 0% |
How did 43 perform over the long term?
See historical performance and comparison